Pemphigus Vulgaris Treatment Market Forecast, Trend Analysis & Competition Tracking - Global Market Insights 2018 to 2028

  • Published : Ongoing
  • Category : Healthcare
  • Report Code : FACT2185MR

Pemphigus vulgaris (PV) is a rare auto-immune disorder with less treatment options. It causes painful blisters on the mucous membrane of the eye, genitals, mouth, throat, nose or skin. Pemphigus vulgaris does not depends on age of a person, it can affect anybody. Pemphigus vulgaris mainly develops due to adverse drug reaction (ADR) of drugs such as enalapril, captopril, penicillamine, some antibiotics, etc. Based on the severity of symptoms, sometimes the patients need to be hospitalized as the disease is life-threatening. Several drugs for the treatment of pemphigus vulgaris such as Corticosteroids and Immunosuppressant are available worldwide. Nowadays, biological treatment such as Rituximab is considered as new approach for pemphigus vulgaris treatment. Most of the randomized, controlled clinical studies have proved Rituximab as a first-line drug for pemphigus vulgaris treatment. In 2017, the FDA approved “Breakthrough Designation” status to MabThera (F. Hoffmann-La Roche Ltd) for pemphigus vulgaris treatment. The objective of pemphigus vulgaris treatment is to reduce blister formation, initiate healing of the erosions and reduce dose of medications to the lowest possible dose. There is no particular cure for pemphigus vulgaris, but pemphigus vulgaris treatment can help prevent the aggravation of the symptoms. 

Pemphigus Vulgaris Treatment Market: Drivers and Restraints

The increasing demand for biological therapies for pemphigus vulgaris treatment is because of their less side effects. Whereas, glucocorticoids can lead to several drug-related reactions. The growing demand for Mabs is expected to drive the growth of the pemphigus vulgaris treatment market during the forecast period. As there are less options available in market for pemphigus vulgaris treatment, and various side effects of marketed non-biological drugs, boost up the research for Pemphigus Vulgaris Treatment and its market. However, high cost of biological drugs and its availability are the major factors expected to hinder the growth of the pemphigus vulgaris treatment market. 

Pemphigus Vulgaris Treatment Market: Segmentation

Tentatively, the global pemphigus vulgaris treatment market can be segmented on the basis of types of treatment, route of administration and distribution channel.

Based on Types of Treatment, the global pemphigus vulgaris treatment market is segmented as:

  • Non-biological treatment
    • Corticosteroids
    • Immunosuppressants (Mycophenolate mofetis, Azathioprin)
    • Antibiotics, antifungal or anti-viral medication
    • Other medications (Dapsone)
  • Biological therapies (Mabs or monoclonal antibodies such as, Rituximab) 

Based on the Route of Administration (RoA), the global pemphigus vulgaris treatment market is segmented as:

  • Subcutaneous
  • Peroeral
  • Intravenous

Based on the Distribution Channel, the global pemphigus vulgaris treatment market is segmented as:

  • Retailers
  • Pharmacy
  • E-Commerce

Pemphigus Vulgaris Treatment Market: Overview

The global market for pemphigus vulgaris treatment is expected to witness significant growth over the forecast period due to high demand for biological therapies for pemphigus vulgaris treatment. By RoA, the subcutaneous drug delivery segment is expected to experience high demand, as it delivers the drug directly to the blood stream resulting in less side effects. Among various indications of pemphigus vulgaris treatment, is expected to gain attraction over the forecast period, primarily due to growing prevalence of Pemphigus Vulgaris (PV). Some of the popular brands of Pemphigus Vulgaris Treatment market include MabThera (F. Hoffmann-La Roche Ltd), Prednisone (Sanofi) etc.

Pemphigus Vulgaris Treatment: Regional Outlook

Geographically, the global pemphigus vulgaris treatment market is segmented into North America, Latin America, Europe, CIS & Russia, Asia-Pacific Excluding Japan, Japan and the Middle East & Africa. North America is expected to be the dominant regional market for pemphigus vulgaris treatment on account of growing research and development for novel pemphigus vulgaris treatment along with advancements in the healthcare sector. The Europe pemphigus vulgaris treatment market is expected to account second large revenue share in the global pemphigus vulgaris treatment market over the forecast period owing to increasing prevalence of pemphigus vulgaris in the region. Fast growth is expected in the Asia-Pacific market, due to technological advancement in the health care sector and increasing investment in life-science research.

Pemphigus Vulgaris Treatment: Key Players 

The global pemphigus vulgaris treatment market is highly fragmented with a large number of global players operating. Examples of some of the key players operating in the global pemphigus vulgaris treatment market are F. Hoffmann-La Roche Ltd, Novartis AG, Sanofi, GlaxoSmithClaine, Syntimmune, Argenx, Principia Biopharma, and HanAll Biopharma, among others.

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

The report covers exhaustive analysis on:

  • Market Segments
  • Market Dynamics
  • Market Size
  • Supply & Demand
  • Current Trends/Issues/Challenges
  • Competition & Companies involved
  • Technology
  • Value Chain

Regional analysis includes

  • North America (U.S., Canada)
  • Latin America (Mexico, Brazil, Argentina, Chile, Peru, and Rest of Latin America)
  • Europe [EU -4 (Germany, France, Italy, Spain), BENELUX (Belgium, Netherlands, Luxemburg), NORDIC (Norway, Denmark, Iceland, Sweden), Eastern Europe (Poland, Ukraine, Czech Rep. etc.), Rest of Europe
  • CIS & Russia
  • Japan
  • APEJ (Greater China, India, S. Korea, ASEAN Countries and Rest of APEJ)
  • Middle East & Africa (GCC Countries, Turkey, Iran, Israel, South Africa, Rest of MEA)

Report Highlights:

  • Detailed overview of parent market
  • Changing market dynamics in the industry
  • In-depth market segmentation
  • Historical, current and projected market size in terms of volume and value
  • Recent industry trends and developments
  • Competitive landscape
  • Strategies of key players and products offered
  • Potential and niche segments, geographical regions exhibiting promising growth
  • A neutral perspective on market performance
  • Must-have information for market players to sustain and enhance their market footprint

We are committed towards customer satisfaction and quality service.


Our Clients

Malaysian Cocoa Board
Dunlop International Europe Ltd
Roland Berger
Superior Essex
Commscope
Deloitte

Fact.MR in Media

Benefits of Becoming a Fact.MR Client

  • Access to our global market coverage
  • Periodic updates on your sector
  • Exclusive discounts and offers
  • Greater flexibility for customization
  • Quick-research assistance for ad-hoc needs
  • Access to credible insights Fact.MR analyst interactions
  • Access to Fact.MR tools and research to fuel strategy development